Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119217 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Natalie M Deschenes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuroscience Studies, Queen's University, Kingston, ON K7L 3N6, Canada. Hauptthemen laut MEDLINE: G(M2) Ganglioside, Gangliosidoses, GM2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlycoNet, Cure Tay-Sachs Foundation.
Abstract (Originalsprache)
GM2 gangliosidosis is a group of genetic disorders that result in the accumulation of GM2 ganglioside (GM2) in brain cells, leading to progressive central nervous system (CNS) atrophy and premature death in patients. AB-variant GM2 gangliosidosis (ABGM2) arises from loss-of-function mutations in the GM2 activator protein (GM2AP), which is essential for the breakdown of GM2 in a key catabolic pathway required for CNS lipid homeostasis. In this study, we show that intrathecal delivery of self-complementary adeno-associated virus serotype-9 (scAAV9) harbouring a functional human GM2A transgene (scAAV9.hGM2A) can prevent GM2 accumulation in in GM2AP-deficient mice (Gm2a−/− mice). Additionally, scAAV9.hGM2A efficiently distributes to all tested regions of the CNS within 14 weeks post-injection and remains detectable for the lifespan of these animals (up to 104 weeks). Remarkably, GM2AP expression from the transgene scales with increasing doses of scAAV9.hGM2A (0.5, 1.0 and 2.0 × 1011 vector genomes (vg) per mouse), and this correlates with dose-dependent correction of GM2 accumulation in the brain. No severe adverse events were observed, and comorbidities in treated mice were comparable to those in disease-free cohorts. Lastly, all doses yielded corrective outcomes. These data indicate that scAAV9.hGM2A treatment is relatively non-toxic and tolerable, and biochemically corrects GM2 accumulation in the CNS—the main cause of morbidity and mortality in patients with ABGM2. Importantly, these results constitute proof-of-principle for treating ABGM2 with scAAV9.hGM2A by means of a single intrathecal administration and establish a foundation for future preclinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Neuroscience Studies, Queen's University, Kingston, ON K7L 3N6, Canada.
- Department of Pediatrics, Queen's University, Kingston, ON K7L 2V7, Canada.
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
- Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
ORCID-Profile: Natalie M Deschenes, Steven J Gray
Förderung
- GlycoNet
- Cure Tay-Sachs Foundation
Zitieren
APA
Deschenes, N. M., Cheng, C., Ryckman, A. E., Quinville, B. M., Khanal, P., Mitchell, M., Chen, Z., Sangrar, W., Gray, S. J., & Walia, J. S. (2023). Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119217
Vancouver
Deschenes NM, Cheng C, Ryckman AE, Quinville BM, Khanal P, Mitchell M, et al. Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119217
BibTeX
@article{Deschenes2023,
author = {Deschenes, Natalie M and Cheng, Camilyn and Ryckman, Alex E and Quinville, Brianna M and Khanal, Prem and Mitchell, Melissa and Chen, Zhilin and Sangrar, Waheed and Gray, Steven J and Walia, Jagdeep S},
title = {Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119217}
}
EUVIMED